Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: A phase II study

Journal of Clinical Oncology

Volumn 16, Issue 11, 1998, Pages 3524-3527

  Treat, Joseph ^a   Johnson, Elizabeth ^a   Langer, Corey ^a   Belani, Chandra ^a   Haynes, Brenda ^a   Greenberg, Richard ^a   Rodriquez, Roberto ^a   Drobins, Patricia ^a   Miller Jr , Wallace ^a   Meehan, Lorraine ^a   McKeon, Ann ^a   Devin, Jeanne ^a   Von Roemeling, Reinhard ^a   Viallet, Jean ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; TIRAPAZAMINE;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; FATIGUE; FEMALE; GRANULOCYTOPENIA; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MUSCLE CRAMP; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; VOMITING;

EID: 0031734636     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.11.3524     Document Type: Article

References (24)

1. LeChevalier T, Brisgand D, Douillard J-Y, et al: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients. J Clin Oncol 12:360-367, 1994
2. Bonomi P, Kim K, Change A, et al: Phase III trial comparing etoposide, cisplatin, versus taxol with cisplatin-G-CSF versus taxol-cisplatin in advanced non-small-cell lung cancer. An Eastern Cooperative Oncology Group (ECOG) trial. Lung Cancer 15:382, 1996 (abstr 1145)
3. Bonomi P, Kim K, Kugler J, et al: Comparison of survival for stage IIIB versus stage IV non-small-cell lung cancer (NSCLC) patients treated with etoposide-cisplatin versus Taxol®-cisplatin: An Eastern Cooperative Group (ECOG) trial. Lung Cancer 16:454a, 1997 (abstr 1631)
4. Wozniak AJ, Crowley JJ, Balcerzak SP, et al: Randomized phase III trial of cisplatin (CDDP) vs CDDP plus navelbine (NVB) in treatment of advanced non-small-cell lung cancer (NSCLC): Report of a Southwest Oncology Group study. Lung Cancer 15:374, 1996 (abstr 1110)
5. Cameron R, Fringer J, Taylor C, et al: Practice guidelines for non-small-cell lung cancer. Cancer J 2:S61-S68, 1996 (suppl 3A)
6. Brown JM, Giaccia AJ: Tumor hypoxia: The picture has changed in the 1990s. Int J Radiat Biol 65:95-102, 1994
7. Thomlinson RH, Gray LH: The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 9:539-549, 1955
8. Vaupel PW, Hockel M: Oxygenation status of human tumors, in Vaupel PW, Kelleher DK, Gunderoth M (eds): Tumor Oxygenation. Stuttgart, Germany, Gustav Fischer Verlag, 1995, pp 219-232
9. Grau C, Overgaard J: Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor measured using a local tumor control assay. Radiother Oncol 13:301-309, 1988
10. Graeber TG, Osmanian C, Jacks T, et al: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 379:88-91, 1996
11. Brown JM: SR 4233 (tirapazamine): A new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer 67:1163-1170, 1993
12. Zeman EM, Brown JM, Lemmon MJ, et al: SR-4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 12:1239-1242, 1986
13. Done MJ, Brown JM: Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res 53:4633-4636, 1993
14. Holden SA, Teicher BA, Ara G, et al: Enhancement of alkylating agent activity by SR-4233 in FSaIIC murine fibrosarcoma. J Natl Cancer Inst 84:187-193, 1992
15. Wouters BG, Giaccia AJ, Delahoussaye YM, et al: Tirapazamine induces apoptosis by p53-dependent and p53-independent mechanisms. Proc Am Assoc Cancer Res 38:246, 1997 (abstr 1665)
16. Rodriguez GI, Valdivieso M, Von Hoff DD, et al: A phase I/II trial of the combination of tirapazamine and cisplatin in patients with non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 15:382, 1996 (abstr 1144)
17. DeJager R, Longeval E, Klastersky J, et al: High-dose cisplatin with fluid and mannitol-induced diuresis in advanced lung cancer: A phase II clinical trial. Cancer Treat Rep 62:843-844, 1981
18. Casper ES, Gralla RJ, Kelson DP, et al: Phase II study of high-dose cis-dichloro-diammineplatinum (II) in the treatment of non-small-cell lung cancer. Cancer Treat Rep 63:2107-2109, 1979
19. Done MJ, Brown JM: Potentiation of the anticancer effect of cisplatin by the hypoxic cytotoxin tirapazamine, in Vaupel PW, Kelleher DK, Gunderoth M (eds): Tumor Oxygenation. Stuttgart, Germany, Gustav Fischer Verlag, 1995, pp 125-135
20. Ng K, Miller VA, Grant SC, et al: Phase II trial of tirapazamine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). Lung Cancer 18:32, 1997 (abstr 115, suppl 1)
21. Anand AJ, Bashey B: Newer insights into cisplatin nephrotoxicity. Ann Pharmacother 27:1519-1525, 1993
22. Kris MG, Gralla RJ, Clark RA, et al: Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 3:1379-1384, 1985
23. Kemp G, Rose P, Lurain J, et al: Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14:2101-2112, 1996
24. Gatineau M, Rixie O, Rey A, et al: Phase I/II study of the addition of tirapazamine (TIRA) to cisplatin (CDDP)/navelbine (NVB) in patients with inoperable non-small-cell lung cancer (NSCLC). Eur J Cancer 33:S249, 1997 (abstr 1125, suppl 8)